Pemetrexed maintenance therapy in advanced non-squamous NSCLC: a single institution experience

被引：0
|
作者：
Lunghi, A. [1 ]
Mazzoni, F. [1 ]
Petreni, P. [1 ]
Vannini, A. [1 ]
Brugia, M. [1 ]
Calamai, V. [1 ]
Di Costanzo, F. [1 ]
机构：
[1] Azienda Osped Univ Careggi, SC Oncol Med, Florence, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
H52
引用
收藏
页码：88 / 89
页数：2
相关论文
共 50 条
  • [1] Maintenance Therapy in advanced, non-squamous NSCLC Possibility of prolongued Tumor Controll with Pemetrexed
    不详
    ONKOLOGIE, 2012, 35 (06): : 390 - 391
  • [2] Maintenance Therapy in advanced non-squamous NSCLC With Pemetrexed a Survival Advantage can be achieved
    不详
    ONKOLOGIE, 2012, 35 (09):
  • [3] Patients with advanced Non-Squamous NSCLC: Experience with Bevacizumab in the continuous Maintenance Therapy
    Bornkessel, Barbara
    ONKOLOGIE, 2012, 35 (06): : 395 - 395
  • [4] MAINTENANCE THERAPY WITH PEMETREXED IMMEDIATELY FOLLOWING INDUCTION TREATMENT WITH PEMETREXED PLUS CISPLATIN FOR ADVANCED NON-SMALL-CELL NON-SQUAMOUS CARCINOMA OF THE LUNG: A SINGLE INSTITUTION'S EXPERIENCE
    Kim, D. H.
    Kinmond, A.
    Gilani, S.
    Giridharan, S.
    Sule-Suso, J.
    Jegannathen, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E13 - E13
  • [5] ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
    Ramalingam, Suresh S.
    Dahlberg, Suzanne Eleanor
    Belani, Chandra Prakash
    Saltzman, Joel N.
    Nambudiri, Gopakumar S.
    McCann, John
    Winegarden, Jerome D.
    Kassem, Mohammed Azher
    Mohamed, K. Mohamed
    Rothman, Jan M.
    Lyss, Alan P.
    Horn, Leora
    Stinchcombe, Tom
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Maintenance pemetrexed immediately following induction treatment with pemetrexed plus cisplatin for advanced non-small-cell non-squamous carcinoma of the lung - a single institution experience
    Kim, D.
    Gilani, S. N.
    Giridharan, S.
    Sule-Suso, J.
    Jegannathen, A.
    LUNG CANCER, 2015, 87 : S24 - S24
  • [7] A Phase II Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed in Elderly Patients with Advanced Non-Squamous NSCLC
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Goto, Koichi
    Yoh, Kiyotaka
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Tanaka, Hiroshi
    Abe, Tetsuya
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S316 - S316
  • [8] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience
    Faber, Mark G.
    Wang, Chong
    Reddy, Sruthi Kommi
    Meagher, Alison
    Early, Amy
    Chen, Hongbin
    Dy, Grace K.
    LUNG CANCER, 2022, 165 : 49 - 53
  • [10] PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC
    Qin, Y.
    Jiang, L.
    Li, Y.
    Ren, L.
    Wang, Y.
    Gong, Y.
    Peng, F.
    Zhu, J.
    Ding, Z.
    Liu, Y.
    Yu, M.
    Lu, Y.
    Huang, M.
    ANNALS OF ONCOLOGY, 2019, 30
12345